



## **Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents**

Downloaded from <http://aidsinfo.nih.gov/guidelines> on 3/18/2013

Visit the *AIDSinfo* website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at <http://aidsinfo.nih.gov/e-news>.

**Appendix B, Table 5. Characteristics of Fusion Inhibitor (Last updated January 29, 2008; last reviewed February 12, 2013)**

Generic Name (Abbreviation)/ Trade Name	Formulations	Dosing Recommendations	Serum Half-Life	Elimination	Storage	Adverse Events (Also see Table 13.)
<b>Enfuvirtide</b> (T20)/ Fuzeon	<ul style="list-style-type: none"> <li>Injectable; supplied as lyophilized powder</li> <li>Each vial contains 108 mg of T20; reconstitute with 1.1 mL of sterile water for injection for delivery of approximately 90 mg/1 mL.</li> </ul>	90 mg (1 mL) subcutaneously BID	3.8 hours	Expected to undergo catabolism to its constituent amino acids, with subsequent recycling of the amino acids in the body pool	Store at room temperature (up to 25°C or 77°F). Reconstituted solution should be refrigerated at 2°C–8°C (36°F–46°F) and used within 24 hours.	<ul style="list-style-type: none"> <li>Local injection site reactions (e.g., pain, erythema, induration, nodules and cysts, pruritus, ecchymosis) in almost 100% of patients</li> <li>Increased incidence of bacterial pneumonia</li> <li>HSR (&lt;1% of patients): Symptoms may include rash, fever, nausea, vomiting, chills, rigors, hypotension, or elevated serum transaminases. Re-challenge is not recommended.</li> </ul>

**Key to Abbreviations:** BID = twice daily, HSR = hypersensitivity reaction, T20 = enfuvirtide

**Appendix B, Table 6. Characteristics of CCR5 Antagonist (Last updated March 27, 2012; last reviewed February 12, 2013)**

Generic Name (Abbreviation)/ Trade Name	Formulation	Dosing Recommendations (For dosage adjustment in hepatic insufficiency, see Appendix B, Table 7.)	Serum Half-Life	Elimination	Adverse Events (Also see Table 13.)
<b>Maraviroc</b> (MVC)/ Selzentry	150 and 300 mg tablets	<p><b>150 mg BID</b> when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers) including PIs (except TPV/r)</p> <p><b>300 mg BID</b> when given with NRTIs, T20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers</p> <p><b>600 mg BID</b> when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor)</p> <p>Take without regard to meals</p>	14–18 hours	CYP3A4 substrate	<ul style="list-style-type: none"> <li>Abdominal pain</li> <li>Cough</li> <li>Dizziness</li> <li>Musculoskeletal symptoms</li> <li>Pyrexia</li> <li>Rash</li> <li>Upper respiratory tract infections</li> <li>Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions</li> <li>Orthostatic hypotension, especially in patients with severe renal insufficiency</li> </ul>

**Key to Abbreviations:** BID = twice daily, CYP = cytochrome P, EFV = efavirenz, ETR = etravirine, MVC = maraviroc, NRTI = nucleoside reverse transcriptase inhibitor, NVP = nevirapine, PI = protease inhibitor, RAL = raltegravir, T20 = enfuvirtide, TPV/r = tipranavir + ritonavir